KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Invested Capital: 2018-2024

Historic Invested Capital for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to -$292.0 million.

  • Esperion Therapeutics' Invested Capital rose 62.87% to -$137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.5 million, marking a year-over-year increase of 62.87%. This contributed to the annual value of -$292.0 million for FY2024, which is 51.00% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Invested Capital of -$292.0 million as of FY2024, which was down 51.00% from -$193.4 million recorded in FY2023.
  • Esperion Therapeutics' Invested Capital's 5-year high stood at -$96.1 million during FY2020, with a 5-year trough of -$323.8 million in FY2022.
  • Its 3-year average for Invested Capital is -$269.7 million, with a median of -$292.0 million in 2024.
  • As far as peak fluctuations go, Esperion Therapeutics' Invested Capital plummeted by 581.87% in 2020, and later surged by 40.27% in 2023.
  • Esperion Therapeutics' Invested Capital (Yearly) stood at -$96.1 million in 2020, then tumbled by 104.86% to -$196.9 million in 2021, then slumped by 64.40% to -$323.8 million in 2022, then soared by 40.27% to -$193.4 million in 2023, then plummeted by 51.00% to -$292.0 million in 2024.